They say the best teacher is the experience. With more than 25 years working in biotechnology, pharmaceuticals, devices and diagnostics fields leave Marc Beer the best teacher to develop Renovia Inc. Marc together with Ramon Iglesias, MD, and Yolanda Lorie joined hands and founded Renovia, a Boston based med-tech industry in August 2016 and successfully closed a Series A funding from top healthcare venture capital funds. Prior to founding Renovia, Marc worked in several companies including Abbott Laboratories where he served as sales and marketing expert. He has also been part of founding teams in various institutions such as Good Start Genetics where Marc was the Founding Chairman of the board of directors and also served as chairman to the compensation committee.
Recently, Marc Beer raised $42 million to boost the operations in Renovia. The funds were distributed in two cycles, first being $32 million Series B round and the second cycle worth $10 million in venture debt. The health care company is aiming to produce various diagnostic and therapeutic products which will help in the treatment of pelvic floor ailments like urinary incontinence. According to the report released by researchers, it is estimated that about 200 million women in the world suffer from these disorders related to the pelvic floor — the previous products released meet the standards for human use as it’s evident from the approval of one of their first product, Leva by FDA.
Series B round was led by a team of Advisors from New York and Ascension Ventures from Missouri also the Longwood Fund, a health-care investing firm which previously had invested in Series A joined the Series B round. The fund is expected to be invested in development and testing of additional four diagnostic and therapeutic products as well as a new advanced brand of the Leva device.
According to the CEO, Marc Beer, the support they have been receiving from these leading health-care investors who share a common vision of improving the lives of millions of women affected with pelvic floor disorders through the provision of better products to diagnose and treat is of value to the company. He added that, through combining innovative and proprietary sensor technologies and creating digital health platforms, clients would be in a better side as they will be receiving valuable data to alert them of new treatment options developed, gain the knowledge and a better understanding of pelvic floor disorders and essential of all lower treatment cost.
Marc Beer works with the help of other officials, who are determined and focused in bringing the vision of Renovia to reality. Some of the management team are:
- William Dull, serving as the Chief Commercial Officer managing international commercial and company operations
- Dr. Samantha Pulliam, MD (Mandy) serving as the Chief Medical Officer.
Learn more: https://renoviainc.com/leadership/